Pratik S. Multani - 15 Dec 2025 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Reporting relationship: Chief Medical Officer
Issuer ticker: ORIC
Reported as of: 15 Dec 2025
Net transaction value: -$97,129
SEC form: 4
Accepted by SEC: 17 Dec 2025, 19:21:01 UTC
Prior SEC filing: 26 Jun 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Christian Kuhlen, attorney-in-fact

Key filing fact

Pratik S. Multani filed Form 4 for Oric Pharmaceuticals, Inc. (ORIC) on 17 Dec 2025.

Key facts

This page summarizes Pratik S. Multani's Form 4 filing for Oric Pharmaceuticals, Inc. (ORIC).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 17 Dec 2025, 19:21.

Change

Previous filing in this sequence was filed on 26 Jun 2025.
Current net transaction value: -$97,129.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001586894 Primary reporting owner

Multani Pratik S

Relationship: Chief Medical Officer
Address: C/O ORIC PHARMACEUTICALS, INC., 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Christian Kuhlen, attorney-in-fact
Signature date: 17 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORIC transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +29,333
Change %: +59%
Price: $0.000000
Shares after: 78,869
Date: 15 Dec 2025
Ownership: Direct
Footnotes: F1, F2

ORIC transaction

Common Stock

Sale

Transaction value: $97,129
Shares: -10,720
Change %: -14%
Price: $9.06
Shares after: 68,149
Date: 16 Dec 2025
Ownership: Direct
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORIC transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -8,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 15 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price
Footnotes: F1, F5

ORIC transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -10,000
Change %: -50%
Price: $0.000000
Shares after: 10,000
Date: 15 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price
Footnotes: F1, F6

ORIC transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -11,333
Change %: -33%
Price: $0.000000
Shares after: 22,667
Date: 15 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,333
Exercise price
Footnotes: F1, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

Footnote F2

Includes an aggregate of 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

Footnote F3

Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

Footnote F4

Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0449 to $9.1451 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F5

1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.

Footnote F6

1/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.

Footnote F7

1/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.